Navigation Links
Benefits of radionuclide therapy for neuroendocrine tumors
Date:9/20/2011

Reston, Va. (September 20, 2011) According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis. While many neuroendocrine cancers are incurable, they grow relatively slowly, and life expectancy is relatively long, making quality of life an important factor in treatment.

In particular, the study "Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Try3]Octreotate" focused on gastroenteropancreatic or bronchial neuroendocrine tumors. These tumors are relatively rare neoplasms that derive from the neuroendocrine system; they affect approximately 1-2.5 individuals per 100,000. Since they often have unpredictable biological behavior, the time from discovery to final diagnosis of the tumors is frequently delayed.

"In patients with gastroenteropancreatic or bronchial neuroendocrine tumors, median progression-free survival after therapy with 177Lu-octreotate is 40 months. Such a survival is promising only if the years that are gained are free of serious side-effects or symptoms that affect quality of life," said Saima Khan, MD, lead author of the study. "We showed that the years gained after this therapy show an improved quality of life, as judged by the patients themselves, according to a validated questionnaire. Moreover, this type of treatment lacks most of the serious adverse events and symptoms that are typical with chemotherapeutic agents."

For the study, 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors were treated with the radiolabeled pharmaceutical 177Lu-octreotate. Follow-up visits were scheduled at fixed time points: six weeks, three months and six months after the last treatment cycle and biannually thereafter. In addition to imaging scans and blood work, patients also completed the European Organisation for Research and Treatment of Cancer quality of life questionnairewhich measures levels of fatigue, nausea plus vomiting, pain, shortness of breath, insomnia, appetite loss, constipation and diarrhea, as well as physical, emotional, role, cognitive and social functioningat each visit. A baseline questionnaire also was completed prior to therapy.

Computer tomography and magnetic resonance imaging were utilized to categorize tumor response into three groupsa remission group, a stable disease group and a progressive disease group. Among all groups, significant improvement in emotional and social functioning, insomnia, appetite loss and diarrhea was noted. The most important improvements, such as diarrhea, pain, nausea and vomiting, were observed in patients who had tumor regression after therapy with 177Lu-octreotate, which suggests that the improvement was a direct result of the treatment.

"It seems highly desirable that in future studies on the efficacy of antitumor agentswhether with radiopharmaceuticals or other drugsquality of life evaluation forms be part of the evaluation of overall efficacy," noted Khan.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
2. 1Dental.com Enhances Dental Plan Benefits With New Fee Schedule
3. Freedom Healthnet Affirms Affordable Private Health Insurance Benefits
4. Surgeon General with Microsoft HealthVault Expands Consumer Benefits for the My Family Health Portrait Offering
5. DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health
6. Greenway Medical Technologies Advances Patient-Provider Benefits
7. LG Electronics Expands Benefits of Healthcare HDTVs With New Compliance Ratings at HIMSS 2010
8. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
9. New study questions benefits of elective removal of ovaries during hysterectomy
10. Health Benefits Direct Announces Extension of Expiration of Rights Offering to March 26, 2010
11. Study evaluates costs and benefits of new chemotherapy drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric cardiovascular surgeons, cardiologists and ... making data on heart procedures public and easily understandable for families and patients ... of Pediatric and Congenital Heart Disease Outcomes will bring hundreds of pediatric heart ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... seeking candidates for the Board of Commissioners. Individuals interested in volunteer board service ... with diversity of clinical practice settings and across allied health to contribute to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, ... of 334 spine surgeons to know in 2016 . The list consists of ... of spine surgery. , Dr. Corenman understands the importance of clinical excellence; he ...
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
(Date:2/11/2016)... ... ... Husted Kicking has completed its Third Annual Husted Kicking College ... 2016 according to kicking coach Michael Husted. , “This event serves as an official ... Indianapolis,” says Husted. “The NFL uses a third party organization to select players for ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- --> --> Transparency ... titled "Sports Medicine Devices Market - Global Industry Analysis, Size, ... the report, the global sports medicine devices market is anticipated ... growing from a value of US$6.1 bn in 2012 to ... --> The global sports medicine devices market is fueled ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology: